Products

MRCP+
Perspectum Diagnostics
Gastroenterology AI
MRCP+ by Perspectum Diagnostics is an AI-powered advanced biliary visualization software that enhances MRCP images to provide quantitative assessment and improved 3D visualization of the biliary tree and pancreatic duct, aiding in the diagnosis and monitoring of pancreatobiliary diseases like Primary Sclerosing Cholangitis (PSC).

See all 1 product →

About Perspectum Diagnostics

Perspectum is a precision health company that leverages artificial intelligence and advanced imaging solutions to provide non-invasive diagnostics for a range of chronic diseases. For physicians, their proprietary technology extracts quantitative biomarkers from multiparametric MRI scans, offering a more comprehensive and objective view of organ health than conventional diagnostics. The company’s flagship product, LiverMultiScan, is designed to accurately measure liver fat, iron, fibrosis, and inflammation, aiding in the early detection, diagnosis, and monitoring of liver conditions such as Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH). This approach aims to reduce reliance on invasive procedures like liver biopsies, improving patient comfort and safety while providing crucial data for clinical decision-making.

Beyond liver health, Perspectum is expanding its portfolio to address multi-organ conditions and oncology. Their AI-driven software enhances standard MRI capabilities to capture and analyze detailed mapping data, enabling precise measurement of organ inflammation and other critical indicators across various systemic diseases. Products like MRCP+ for bile ducts and pancreas, and CoverScan for multi-organ assessment in conditions like long COVID, demonstrate their commitment to a holistic, patient-first approach. The company’s solutions are designed to integrate seamlessly into existing clinical workflows, providing actionable data intelligence to personalize care and improve patient outcomes.

Focus Areas

Liver disease metabolic diseases cancer multi-organ pathology long COVID precision medicine AI-driven solutions quantitative imaging digital health diagnostics drug development biomarkers

Business Intelligence

Key InvestorsOppenheimer, Blue Venture Fund, HealthQuest Capital, Oxford Science Innovation, Puhua Capital, University of Oxford, Oxford University Hospitals NHS Foundation Trust
PartnershipsInHealth (UK), Avant Santé (Mexico/Latin America), Oxford University Hospitals NHS Foundation Trust, Precious Medical Centre (Singapore), University of Westminster
TechnologyCloud-native, AI-driven software, multiparametric MRI, software-as-a-service (SaaS) platform, computer vision, proprietary biomarkers, vendor-agnostic disease mapping
FDA Clearances5 cleared products (estimated)

What Physicians Need to Know

Specialized Disease Areas
Perspectum Diagnostics specializes in comprehensive assessment and management of liver disease (including MASLD/MASH, viral hepatitis, liver cancer, autoimmune, and biliary conditions like PSC), metabolic diseases (such as diabetes and obesity), various cancers, and multi-organ pathology, including long COVID.
Core Technology & Approach
They leverage proprietary multiparametric MRI (mpMRI) and quantitative imaging to extract detailed biomarkers, providing a non-invasive, objective, and reproducible assessment of tissue characteristics. Their solutions are AI-driven, utilizing computer vision and machine learning for enhanced analysis and decision support.
Digital Health & AI Solutions
Perspectum offers digital health solutions delivered as secure, cloud-based Software as a Service (SaaS). Their AI-powered platforms, such as LiverMultiScan, CoverScan, MRCP+, and Hepatica, provide integrated data intelligence and patient-friendly reports, aiming to replace invasive procedures like liver biopsies.
Drug Development & Biomarkers
The company provides proprietary imaging biomarkers for the identification and monitoring of disease in clinical trials, supporting drug development across various therapeutic areas. Their technology aims to close the loop on drug development by offering companion diagnostics and reducing the need for biopsies in trials.
Key Differentiators
Perspectum's key differentiators include their non-invasive approach, offering safer, painless, and cost-effective alternatives to biopsies; their ability to provide a fuller, integrated data picture compared to conventional diagnostics; and their patient-first philosophy focused on personalized care. They are a University of Oxford spin-out, backed by renowned physicians and scientists.
Physician Tip

For physicians, Perspectum Diagnostics offers advanced, non-invasive imaging solutions that provide objective, quantitative, and reproducible data for earlier detection, more accurate diagnosis, and targeted treatment of complex chronic diseases. Their multi-organ assessment tools, like CoverScan, allow for a holistic view of patient health from a single MRI scan. The AI-driven, cloud-based platforms streamline workflows, deliver easy-to-interpret reports, and can significantly reduce reliance on invasive procedures such as liver biopsies, improving patient safety and experience. This technology supports precision medicine by enabling personalized care plans and offers valuable biomarkers for monitoring disease progression and assessing treatment efficacy in both clinical practice and drug development.

Perspectum's solutions are delivered as cloud-based Software as a Service (SaaS), leveraging existing MRI hardware infrastructure without requiring new equipment installation. Data from MRI scans are securely sent to their dedicated reporting center for AI-powered analysis and returned as patient-friendly reports. They integrate into clinical workflows and have established partnerships, such as with Nuance (a Microsoft company), to scale access to their AI-enabled platforms and facilitate seamless sharing of insights within healthcare facilities.

Products by Perspectum Diagnostics

1 product in the directory

MRCP+
Perspectum Diagnostics
Gastroenterology AI
MRCP+ by Perspectum Diagnostics is an AI-powered advanced biliary visualization software that enhances MRCP images to provide quantitative assessment and improved 3D visualization of the biliary tree and pancreatic duct, aiding in the diagnosis and monitoring of pancreatobiliary diseases like Primary Sclerosing Cholangitis (PSC).

What the Web Says

Perspectum Diagnostics is a company focused on developing advanced imaging solutions for the diagnosis and management of chronic systemic diseases, particularly liver conditions. Their flagship product, LiverMultiScan, is a non-invasive MRI-based tool that aims to provide more comprehensive insights than traditional diagnostics. The company emphasizes a patient-first approach and aims to improve clinical decision-making and patient outcomes. While product reviews highlight the benefits of their technology in patient care and cost-effectiveness, employer reviews are mixed, with some concerns about management and career advancement.

Overall: Mixed

Strengths

  • Advanced imaging solutions for comprehensive diagnostics
  • Non-invasive and safer than traditional methods like liver biopsy
  • Can improve patient understanding of their condition
  • Potential for significant cost savings in healthcare
  • Good company perks like gym discount and private health insurance (employer review)
  • Flexible work-from-home policy (employer review)

Limitations

  • Some senior management members unwilling to provide guidance or tasks (employer review)
  • Inexperienced management that may not follow rules or regulations (employer review)
  • Lack of structure or room to grow (employer review)
  • Management issues, including being unresponsive and micromanaging (employer review)
  • Low pay in some roles (employer review)
  • High turnover in some departments (employer review)

Based on reviews from: Indeed.com, AuntMinnie, PharmaTimes, Perspectum.com, Medical Technology Enterprise Consortium (MTEC)

Last updated: 2026-07-19

Videos

News, demos, and interviews about Perspectum Diagnostics.

Loading videos...

Videos load interactively. If none appear, search YouTube for Perspectum Diagnostics →

View all on YouTube

Press & Coverage

Perspectum
Sir Mike Brady Elected as an International Member of the National Academy of Engineering
Sir Michael Brady, co-founder of Perspectum, has been elected to the National Academy of Engineering (NAE), one of the highest professional distinctions for engineers.
2026-02
Perspectum
Perspectum Announces Executive Leadership Changes
Dr. Rajarshi Banerjee is no longer with Perspectum, and Dr. Rexford Newbould, the company's Chief Operating Officer, has been appointed as Interim Chief.
2026-01
Perspectum
Perspectum and Avant Santu00e9 announce strategic partnership to strengthen quantitative imaging for metabolic and liver research in Mexico and Latin America
Perspectum has partnered with Avant Santu00e9 to enhance quantitative imaging for metabolic and liver research in Mexico and Latin America.
2025-12
Perspectum
Perspectum and InHealth announce national diagnostics partnership to boost Oxford CDC capacity and widen access to advanced MRI across the UK
This partnership aims to significantly expand access to advanced MRI and increase capacity at the Oxford Community Diagnostic Centre (CDC) in the UK.
2025-12
Perspectum
New analysis shows corrected T1 (cT1) is the most appropriate diagnosis and monitoring tool for widespread adoption of resmetirom treatment in the United States
Economic modeling suggests that Perspectum's proprietary biomarker cT1 is the most suitable tool for diagnosing and monitoring resmetirom treatment in the US.
2025-09
Perspectum
Perspectum Awarded New FDA Grant to Evaluate Biomarker for Rare Disease Drug Development
Perspectum received a 2024 U.S. Food and Drug Administration Drug Development Tool (DDT) Research Grant to evaluate a novel biomarker for rare diseases.
2024-11
MedCity News
Perspectum Completes $55M Series C to Improve Metabolic Disease Diagnosis
Perspectum announced the second close of its $55 million Series C funding round, securing an additional $19 million investment led by Oppenheimer, bringing total funding to approximately $140 million.
2023-03
Perspectum
New meta-analysis finds Perspectum's non-invasive MRI biomarker cT1 is an effective alternative to biopsy for identifying patients at high risk of liver disease progression
A new meta-analysis published in Clinical Gastroenterology and Hepatology found that LiverMultiScanu00ae cT1 can accurately identify NASH patients at high risk of disease progression, offering a non-invasive alternative to biopsy.
2022-01

Frequently Asked Questions

Perspectum offers LiverMultiScan for comprehensive liver health assessment, quantifying fat, iron, fibrosis, and inflammation non-invasively. For broader metabolic and multi-organ assessment, CoverScan evaluates six organs in a single MRI scan, including liver, heart, and pancreas. These solutions improve patient management by enabling early detection, personalized treatment, reducing the need for invasive biopsies, and proving cost-effective in diagnosing and monitoring conditions like Steatotic Liver Disease (SLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH).
Perspectum leverages AI and quantitative MRI to extract precise biomarkers from imaging, enhancing diagnostic accuracy and supporting precision medicine by tailoring care to individual patient needs. Their CoverScan technology, developed through Long COVID research, assesses multi-organ impairment across six organs (heart, lungs, kidneys, liver, pancreas, spleen), demonstrating a physiological basis for the condition. For oncology, they offer integrated analysis of multi-organ and tumor characterization, supporting drug development and clinical trials.
Perspectum's flagship product, LiverMultiScan, is FDA-cleared in the United States, having received 510(k) clearance. The company maintains a robust compliance framework, adhering to international standards such as ISO 27001 for information security and ISO 13485:2016, 21 CFR 820, and IEC 62304:2006 for software validation. Their dedicated Regulatory Affairs team ensures ongoing adherence to applicable regulations and standards across key markets.
Perspectum's solutions provide proprietary imaging biomarkers for the identification and monitoring of disease in clinical trials, delivered as a secure, cloud-based software-as-a-service. Their technology, like LiverMultiScan, is used by pharmaceutical companies to identify suitable patients for trials and monitor therapeutic efficacy, particularly in areas like NASH and NAFLD. This approach reduces the reliance on invasive liver biopsies in clinical trials and has received FDA grants for biomarker evaluation in rare disease drug development.
Perspectum places a strong emphasis on education and training, offering comprehensive programs to ensure healthcare professionals can effectively utilize their diagnostic tools. They provide a Medical Education Hub with various resources, including publications and conference information, to support continuous learning. Additionally, direct contact channels are available for product inquiries and clinical support, facilitating seamless integration of their digital health solutions into clinical workflows.
Perspectum's LiverMultiScan is recognized as a cost-effective diagnostic tool, reducing the need for expensive and invasive procedures like liver biopsies, leading to lower per-patient costs. In terms of accessibility, LiverMultiScan has widespread insurance coverage in the U.S., including Medicare and commercial plans. Perspectum is actively expanding access through strategic partnerships, such as with InHealth in the UK and Nuance Communications in the US, to integrate their solutions into more healthcare facilities.
Perspectum, founded in 2012 as an Oxford University spin-out, has established strategic partnerships with leading academic institutions, pharmaceutical companies, and digital health providers like Nuance Communications (a Microsoft company) and InHealth. The company demonstrated stability by raising $36 million in Series C funding in 2023, totaling $120 million, to expand its U.S. presence and accelerate its product pipeline. Their vision is to build a better future for patients through scientific innovation, integrated data intelligence, and non-invasive diagnostics, focusing on early detection and personalized treatment of chronic systemic diseases.

Related Companies

CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]

Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]

OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]

Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]

MedTalk AI is an Australian-based healthcare AI company focused on streamlining clinical documentation for physicians and other healthcare professionals. The company’s flagship product is an ambient AI medical scribe that listens to real clinical conversations and converts them into structured, accurate notes in real-time. This technology aims to free clinicians from the burden of manual […]

allergoSMART is a healthcare AI company that offers the world’s first AI-based complete solution for personalized mite allergen avoidance. The company’s system, allergoSMART, provides a unique AI digital solution for individuals with dust mite allergies, combining targeted prevention and treatment through comprehensive home environment optimization. [3] It integrates symptom tracking, telemedicine, and air purification into […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.